 The principal aim is to investigate the safety and efficacy of rosiglitazone in patients with chronic systolic heart Dilated cardiomyopathy. We hypothesize that in patients with heart failure, rosiglitazone is safe, and can reduce nitric oxide NO derived oxidative stress in particular, nitrotyrosine thereby improving endothelial dysfunction, left ventricular performance, and metabolic parameters. 